Pub Date : 2021-09-05DOI: 10.32756/0869-5490-2021-3-52-56
J. E. Netylko, M. Teterina, A. Pisaryuk, L. Goreva, O. Lukina, A. Safarova, I. Merai, Z. Kobalava
To assess the value of echocardiographic parameters in predicting hospital death in patients with pulmonary embolism (PE).
目的探讨超声心动图参数在预测肺栓塞(PE)患者住院死亡中的价值。
{"title":"Prognostic value of echocardiographic parameters in patients with pulmonary embolism","authors":"J. E. Netylko, M. Teterina, A. Pisaryuk, L. Goreva, O. Lukina, A. Safarova, I. Merai, Z. Kobalava","doi":"10.32756/0869-5490-2021-3-52-56","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-3-52-56","url":null,"abstract":"To assess the value of echocardiographic parameters in predicting hospital death in patients with pulmonary embolism (PE).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81430703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-05DOI: 10.32756/0869-5490-2021-3-18-24
E. Katunina
In a review article, the author discusses the mechanisms of spasticity after stroke, its clinical manifestations and approaches to treatment including physical therapy, surgery and the use of central (tolperisone, baclophen and tizanidine) and peripheral (botulinum toxin A) acting muscle relaxants.
{"title":"Pathogenesis and treatment of spasticity","authors":"E. Katunina","doi":"10.32756/0869-5490-2021-3-18-24","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-3-18-24","url":null,"abstract":"In a review article, the author discusses the mechanisms of spasticity after stroke, its clinical manifestations and approaches to treatment including physical therapy, surgery and the use of central (tolperisone, baclophen and tizanidine) and peripheral (botulinum toxin A) acting muscle relaxants.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77731563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-05DOI: 10.32756/0869-5490-2021-3-25-30
Y. Korotchaeva, N. Kozlovskaya, E. Shifman
Obstetric atypical hemolytic-uremic syndrome (aHUS) is an emergency with an unfavorable prognosis. The implementation of the complement-blocking drug Eculizumab into clinical practice significantly improved prognosis of patients with obstetric aHUS. In 2019, the first biosimilar of Eculizumab was developed in Russia by GENERIUM.
{"title":"Comparative efficacy of the original and biosimilar eculizumab in the treatment of obstetric atypical hemolytic-uremic syndrome","authors":"Y. Korotchaeva, N. Kozlovskaya, E. Shifman","doi":"10.32756/0869-5490-2021-3-25-30","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-3-25-30","url":null,"abstract":"Obstetric atypical hemolytic-uremic syndrome (aHUS) is an emergency with an unfavorable prognosis. The implementation of the complement-blocking drug Eculizumab into clinical practice significantly improved prognosis of patients with obstetric aHUS. In 2019, the first biosimilar of Eculizumab was developed in Russia by GENERIUM.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79196190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-05DOI: 10.32756/0869-5490-2021-3-31-37
E.V. Tavlueva, I. G. Ivanov, K. Lytkina, P.A. Plesovskiy, T. V. Bezuglaya, S. Fridman, T. Meleshkevich, V. V. Strizheletskiy, G. Melkonyan, G.Yu. Melik-Ogandzhanyan, M. Uyanaeva, E. A. Bezuglaya, D. N. Khobotnikov, P. Pukhtinskaia, V. Mladov
To evaluate the efficacy and safety of levilimab in COVID-19 patients in the real-life clinical practice.
在临床实践中评价利来单抗治疗新冠肺炎患者的疗效和安全性。
{"title":"Levilimab in patients with COVID-19 in real-life practice","authors":"E.V. Tavlueva, I. G. Ivanov, K. Lytkina, P.A. Plesovskiy, T. V. Bezuglaya, S. Fridman, T. Meleshkevich, V. V. Strizheletskiy, G. Melkonyan, G.Yu. Melik-Ogandzhanyan, M. Uyanaeva, E. A. Bezuglaya, D. N. Khobotnikov, P. Pukhtinskaia, V. Mladov","doi":"10.32756/0869-5490-2021-3-31-37","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-3-31-37","url":null,"abstract":"To evaluate the efficacy and safety of levilimab in COVID-19 patients in the real-life clinical practice.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86922335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-05DOI: 10.32756/0869-5490-2021-3-57-66
S. Moiseev
A history of stroke or transient ischemic attack (TIA) in patients with nonvalvular atrial fibrillation (AF) is associated with a two-fold increase in risk of recurrent stroke. Without anticoagulation the annual incidence of recurrent stroke in these patients ranges from 6% to 9% and significantly exceeds this in patients with other risk factors for thromboembolic events. Meta-analysis of randomised clinical trials (RCT) suggested that direct oral anticoagulants (DOAC) are more effective and safe than warfarin and should be preferred treatment in patients with AF and previous stroke/TIA. Several RCTs are investigating optimal timing of (re)initiation of anticoagulation after acute ischemic stroke. Current guidelines suggest that in most patients treatment with anticoagulants may be initiated within 4-14 days after the onset of acute ischemic stroke depending on its severity and infarct size. Aspirin is recommended until oral anticoagulant therapy is initiated.
{"title":"Direct oral anticoagulants for prevention of recurrent stroke in patients with atrial fibrillation","authors":"S. Moiseev","doi":"10.32756/0869-5490-2021-3-57-66","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-3-57-66","url":null,"abstract":"A history of stroke or transient ischemic attack (TIA) in patients with nonvalvular atrial fibrillation (AF) is associated with a two-fold increase in risk of recurrent stroke. Without anticoagulation the annual incidence of recurrent stroke in these patients ranges from 6% to 9% and significantly exceeds this in patients with other risk factors for thromboembolic events. Meta-analysis of randomised clinical trials (RCT) suggested that direct oral anticoagulants (DOAC) are more effective and safe than warfarin and should be preferred treatment in patients with AF and previous stroke/TIA. Several RCTs are investigating optimal timing of (re)initiation of anticoagulation after acute ischemic stroke. Current guidelines suggest that in most patients treatment with anticoagulants may be initiated within 4-14 days after the onset of acute ischemic stroke depending on its severity and infarct size. Aspirin is recommended until oral anticoagulant therapy is initiated.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90354867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-01DOI: 10.32756/0869-5490-2021-2-31-35
T. Shevtsova, V. Nadtocheeva, S. Nimiritskaya, L. Akulkina, N. Bulanov, P. Novikov
To evaluate the effect of intravenous rituximab, a monoclonal antibody to B-cells, on interstitial lung disease, skin fibrosis and arthritis in patients with systemic sclerosis (SSc).
{"title":"Rituximab in systemic sclerosis","authors":"T. Shevtsova, V. Nadtocheeva, S. Nimiritskaya, L. Akulkina, N. Bulanov, P. Novikov","doi":"10.32756/0869-5490-2021-2-31-35","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-2-31-35","url":null,"abstract":"To evaluate the effect of intravenous rituximab, a monoclonal antibody to B-cells, on interstitial lung disease, skin fibrosis and arthritis in patients with systemic sclerosis (SSc).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"13 21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79709295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-01DOI: 10.32756/0869-5490-2021-2-67-74
S. Moiseev, P. Novikov, N. Chebotareva, S. Gulyaev, N. Bulanov, T. Schevtsova, E. Shchegoleva
Olokizumab is a new humanized monoclonal antibody targeting IL-6 that is approved for treatment of patients with moderately severe or severe active rheumatoid arthritis despite therapy with methotrexate and other conventional diseasemodifying antirheumatic drugs or biologic agents. The efficacy and favorable safety profile of olokizumab in combination with methotrexate in rheumatoid arthritis patients who had previously failed methotrexate or tumour necrosis factor inhibitors were established in the several international 3 phase clinical trials (CREDO). The authors present two cases of successful olokizumab administration and discuss the indications for its use in patients with rheumatoid arthritis to achieve clinical improvement and to prevent progression of AA-amyloidosis.
{"title":"Olokizumab for treatment of rheumatoid arthritis","authors":"S. Moiseev, P. Novikov, N. Chebotareva, S. Gulyaev, N. Bulanov, T. Schevtsova, E. Shchegoleva","doi":"10.32756/0869-5490-2021-2-67-74","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-2-67-74","url":null,"abstract":"Olokizumab is a new humanized monoclonal antibody targeting IL-6 that is approved for treatment of patients with moderately severe or severe active rheumatoid arthritis despite therapy with methotrexate and other conventional diseasemodifying antirheumatic drugs or biologic agents. The efficacy and favorable safety profile of olokizumab in combination with methotrexate in rheumatoid arthritis patients who had previously failed methotrexate or tumour necrosis factor inhibitors were established in the several international 3 phase clinical trials (CREDO). The authors present two cases of successful olokizumab administration and discuss the indications for its use in patients with rheumatoid arthritis to achieve clinical improvement and to prevent progression of AA-amyloidosis.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"8 3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90720858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-01DOI: 10.32756/0869-5490-2021-2-44-50
S. Moiseev, V. Rameev
Transthyretin is primarily synthesized in the liver and transports thyroxine and vitamin A in the body. The transthyretin when dissociated into monomers can misfold and ultimately form amyloid fibrils. There are two types of ATTR amyloidosis: hereditary (caused by mutations in the TTR gene) and wild-type (also referred to as senile systemic amyloidosis). Amyloid cardiomyopathy can develop in patients with both types of ATTR amyloidosis, has a later onset and is characterized by progressive heart failure leading to death within a few years after diagnosis. Tafamidis is an oral-administered small molecule that binds to transthyretin and inhibits transthyretin tetramer dissociation, the rate-limiting step in the amyloidosis. Long-term efficacy and safety of tafamidis were shown in patients with transthyretin familial amyloid polyneuropathy. The objective of the phase 3 international, multicenter, double-blind, placebo-controlled, randomized ATTR-ACT study was to evaluate the efficacy, safety, and tolerability of tafamidis (20 or 80 mg orally QD) in comparison with placebo in 441 patients with hereditary and nonhereditary transthyretin cardiomyopathy (median age 75 years, 90% of males). At month 30, treatment with tafamidis was associated with a lower risk of all-cause mortality (by 30%) and a lower rate of cardiovascular related hospitalizations (by 32%) than placebo and resulted in a lower rate of decline in distance for the 6-minute walk test and a lower rate of decline in KCCQ-OS score. The data from extension study supports tafamidis 80 mg as the optimal dose (bioequivalent to tafamidis free acid 61 mg).
{"title":"Tafamidis in transthyretin amyloid cardiomyopathy","authors":"S. Moiseev, V. Rameev","doi":"10.32756/0869-5490-2021-2-44-50","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-2-44-50","url":null,"abstract":"Transthyretin is primarily synthesized in the liver and transports thyroxine and vitamin A in the body. The transthyretin when dissociated into monomers can misfold and ultimately form amyloid fibrils. There are two types of ATTR amyloidosis: hereditary (caused by mutations in the TTR gene) and wild-type (also referred to as senile systemic amyloidosis). Amyloid cardiomyopathy can develop in patients with both types of ATTR amyloidosis, has a later onset and is characterized by progressive heart failure leading to death within a few years after diagnosis. Tafamidis is an oral-administered small molecule that binds to transthyretin and inhibits transthyretin tetramer dissociation, the rate-limiting step in the amyloidosis. Long-term efficacy and safety of tafamidis were shown in patients with transthyretin familial amyloid polyneuropathy. The objective of the phase 3 international, multicenter, double-blind, placebo-controlled, randomized ATTR-ACT study was to evaluate the efficacy, safety, and tolerability of tafamidis (20 or 80 mg orally QD) in comparison with placebo in 441 patients with hereditary and nonhereditary transthyretin cardiomyopathy (median age 75 years, 90% of males). At month 30, treatment with tafamidis was associated with a lower risk of all-cause mortality (by 30%) and a lower rate of cardiovascular related hospitalizations (by 32%) than placebo and resulted in a lower rate of decline in distance for the 6-minute walk test and a lower rate of decline in KCCQ-OS score. The data from extension study supports tafamidis 80 mg as the optimal dose (bioequivalent to tafamidis free acid 61 mg).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73160004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-01DOI: 10.32756/0869-5490-2021-2-59-66
V.N. Drozdovа, E.K. Kochetkovaа
Factor Xa antagonists are used increasingly frequently for prevention and treatment of venous thromboembolic events and for prevention of stroke and systemic emboli in patients with non-valvular atrial fibrillation. Individual characteristics of patient, a need in prolonged or life-long treatment, concomitant diseases, the use of other drugs interacting with anticoagulants increase the risk of side effects of anticoagulation. We analyzed the current data on the efficacy and safety of Xa factor antagonists, as well as the features of their use in the event of adverse reactions, particularly bleedings. The possibilities of monitoring the efficacy and safety of treatment with these drugs were evaluated.
{"title":"Efficacy and safety of Xa factor antagonists in patients with nonvalvular atrial fibrillation","authors":"V.N. Drozdovа, E.K. Kochetkovaа","doi":"10.32756/0869-5490-2021-2-59-66","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-2-59-66","url":null,"abstract":"Factor Xa antagonists are used increasingly frequently for prevention and treatment of venous thromboembolic events and for prevention of stroke and systemic emboli in patients with non-valvular atrial fibrillation. Individual characteristics of patient, a need in prolonged or life-long treatment, concomitant diseases, the use of other drugs interacting with anticoagulants increase the risk of side effects of anticoagulation. We analyzed the current data on the efficacy and safety of Xa factor antagonists, as well as the features of their use in the event of adverse reactions, particularly bleedings. The possibilities of monitoring the efficacy and safety of treatment with these drugs were evaluated.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74004828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-01DOI: 10.32756/0869-5490-2021-2-36-43
V. Rameev, A. Simonyan, M. Bogdanova, L. Lysenko, S. Moiseev
To evaluate diagnostic and treatment issues in patients with familial Mediterranean fever (FMF) and risk factors for AA-amyloidosis.
评估家族性地中海热(FMF)患者的诊断和治疗问题及aa -淀粉样变的危险因素。
{"title":"Familial Mediterranean fever: diagnostic issues and treatment options","authors":"V. Rameev, A. Simonyan, M. Bogdanova, L. Lysenko, S. Moiseev","doi":"10.32756/0869-5490-2021-2-36-43","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-2-36-43","url":null,"abstract":"To evaluate diagnostic and treatment issues in patients with familial Mediterranean fever (FMF) and risk factors for AA-amyloidosis.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75815768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：